Mabqi is focused on the discovery and development of next-generation innovative antibodies and immunotherapies.
We leverage our LiteMab© Antibody Discovery Studio to tackle complex targets, explore next-generation antibody formats and generate highly developable, fully human functional drug candidates.
Mabqi believes in teamwork and open innovation to bring new clinical options to patients. We are your partner of choice to expedite development of new valuable antibody-based therapies. Various options are available for collaborating.
Mabqi’s LiteMab© Antibody Discovery Studio is ideally suited for challenging targets such as transmembrane proteins (GPCRs), ion channels, soluble proteins, peptides and many more.
The core technology is built on a suite of fully human synthetic antibody libraries, combined with AI-powered phage and yeast display technologies.
Our state-of-the-art display platforms expedite antibody discovery workflows by enabling high-throughput antibody selection, screening, and hit identification through rigorous functional validation of fully human antibody candidates.
LiteMab Discovery Studio is designed to enable the discovery of therapeutic antibodies such as conventional mAbs, multispecific antibodies, conditionally active pH senstivive antibodies and Antibody drug conjugates (ADC).
Mabqi is building a robust pipeline of innovative therapeutic antibodies in oncology. Some of our lead candidates have unique pH-sensitive features and are readily convertible to next generation formats such as Antibody Drug Conjugates (ADC), T-cell engagers (TCE), CAR-T therapies.
